D-150 is a potential backbone therapy that is designed to provide multi-year sustained delivery of anti-VEGF (aflibercept and ...

Physicians’ Education Resource (PER) has launched Retina Resource, a comprehensive source of education and information on the ...

Kalaris is focused on developing TH103, a novel, differentiated anti-VEGF agent engineered to potentially provide longer-lasting and increased ...

it is possible that patients with myopic macular degeneration complicated by CNV may benefit from a new ophthalmic frontier of pharmacologic therapy, including intravitreal injections of anti-VEGF ...

The updated guidelines note that patients with stage IV NSCLC who have EGFR exon 19 deletions or exon 21 L858R substitutions can receive osimertinib plus platinum doublet chemotherapy or amivantamab ...

Obstructive sleep apnea is associated with higher rates of age-related macular degeneration development and progression.

Continuous administration of ranibizumab with a port delivery system provides an alternative to frequent intravitreal ...

Physicians’ Education Resource (PER ®) is excited to announce the launch of Retina Resource, a comprehensive source of cutting-edge education and information on the latest innovations in anti-VEGF ...

The FDA approved Encelto, an encapsulated cell therapy, for the treatment of macular ... diabetic macular edema have a weaker response to anti-VEGF treatment, according to a presentation at ...